Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema - Reply

被引：10

作者：

Beck, TR

Baird, LG

机构：

[1] Dyax Corp, Business & Prod Dev, Cambridge, MA 02139 USA

[2] Dyax Corp, Dev, Cambridge, MA 02139 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期

关键词：

D O I：

10.1016/j.jaci.2005.10.044

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：477 / 477

页数：1

共 50 条

[1] Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema
Caballero, T
López-Serrano, C
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : 476 - 477
[2] Inhibitor of human plasma kallikrein DX-88 for the treatment of acute attack in a family with hereditary angioedema
Anne, R
Deveras, E
Bracho, F
[J]. BLOOD, 2004, 104 (11) : 113B - 114B
[3] DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema
Cicardi, M
Gonzalez-Quevedo, T
Caballero, T
Bork, K
Williams, A
[J]. MOLECULAR IMMUNOLOGY, 2003, 40 (2-4) : 197 - 198
[4] DX-88 a recombinant inhibitor of human plasma kallikrein. Evalation of efficacy and safety in patients with hereditary angioedema
Williams, T
Cicardi, M
Bork, K
Gonzalez-Quevedo, T
Caballero, T
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (04) : 908 - 908
[5] Anaphylaxis in response to C1 esterase inhibitor in a patient with hereditary Angioedema - Successful treatment with DX-88, a human plasma kallikrein inhibitor
Zingale, Lorenza C.
Zanichelli, Andrea
Deliliers, Daniela Lambertenghi
Cicardi, Marco
[J]. ALLERGY & CLINICAL IMMUNOLOGY INTERNATIONAL-JOURNAL OF THE WORLD ALLERGY ORGANIZATION, 2007, 19 (04): : 159 - 163
[6] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Lehmann, Andreas
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1187 - 1199
[7] Resolution of bowel obstruction in a patient with hereditary angioedema treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study
Cicardi, Marco
Zingale, Lorenza C.
Zanichelli, Andrea
[J]. MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 160 - 160
[8] Results of a repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88), a recombinant plasma kallikrein inhibitor, in patients with hereditary angioedema.
Lumry, W.
Li, H.
Schneider, L.
Leflein, J.
Craig, T.
Morrison, J.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A29 - A29
[9] A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study
Cicardi, Marco
Zingale, Lorenza C.
Zanichelli, Andrea
[J]. MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 160 - 161
[10] Use of the Thrombelastograph® to assess the in vitro effects of DX-88, a novel kallikrein inhibitor, in cardiopulmonary bypass
Self, R
Mackie, I
Jenkins, A
Sanders, J
Williams, A
Machin, S
Mythen, M
[J]. BRITISH JOURNAL OF ANAESTHESIA, 2004, 93 (02) : 318P - 318P

← 1 2 3 4 5 →